TABLE 1.
Demographic and Baseline Clinical Characteristics of Patients Treated With Vedolizumab
| N = 83 | |
|---|---|
| Female Gender, n (%) | 45 (54.2) |
| Smoker, former or current, n (%) | 19 (22.9) |
| Age at initiation of vedolizumab in years, median (IQR) | 42.1 (31.1–53.4) |
| Extra-intestinal manifestations, n (%) | 43 (51.2) |
| Years from IBD diagnosis to IPAA in years, median (IQR) | 4.9 (2.0–9.9) |
| Years from IPAA to pouchitis in years, median (IQR) | 1.3 (0.7–5.7) |
| Obese (BMI >30), n (%) | 19 (22.9) |
| Pre-operative diagnosis | |
| UC, n (%) | 68 (81.9) |
| CD, n (%) | 9 (10.8) |
| Indeterminate colitis, n (%) | 6 (7.2) |
| Indication for IPAA | |
| Medically refractory disease, n (%) | 79 (95.2) |
| Dysplasia, n (%) | 2 (2.4) |
| Othera, n (%) | 2 (2.4) |
| Infectious complication after IPAA | |
| Presacral abscess, n (%) | 11 (13.3) |
| SSI of ostomy, n (%) | 4 (4.8) |
| Perianal abscess, n (%) | 6 (7.2) |
| Family history of IBD | 26 (31.3) |
| Opioid use | 16 (19.3) |
| Ever had fistula, n (%) | 35 (42.2) |
| Fistula at time of starting vedolizumab | 18 (21.7) |
| Fistula type | |
| Perianal | 17 (20.5) |
| Vaginal | 9 (10.8) |
| Ileal | 3 (3.6) |
| Otherc | 6 (7.2) |
| Ileoanal stricture | 26 (30.3) |
| CD of the pouch b , n (%) | 54 (65.1) |
| Afferent limb stricture | 13 (15.7) |
| Fistula | 31 (37.3) |
| Duration from pouchitis diagnosis to vedolizumab initiation in years, median (IQR) | 3.95 (1.3–8.6) |
| Previous treatments for pouchitis | |
| Topical ASA, n (%) | 18 (21.7) |
| Oral ASA, n (%) | 12 (14.5) |
| Azathioprine or 6MP, n (%) | 29 (34.9) |
| Methotrexate, n (%) | 24 (28.9) |
| Anti-TNF monotherapy, n (%) | 43 (51.8) |
| Anti-TNF + immunomodulator, n (%) | 14 (16.9) |
| Topical steroids, n (%) | 25 (30.1) |
| Systemic corticosteroids, n (%) | 34 (40.9) |
| Antibiotics, n (%) | 72 (86.8) |
ASA, aminosalicylate; SSI, surgical site infection
aOne patient developed pneumatosis coli after receiving the second infliximab induction dose; another patient had a colonic perforation.
bInflammation or stricture of afferent limb or more proximal small bowel, fistula involving perineum or small bowel, fistula involving the pouch >6 months after surgery, granulomas
cIncludes 2 perirectal, 3 perineal, 1 pouch labial